The global infection control market is projected to grow from USD 57.31 billion in 2025 to USD 77.67 billion by 2030, registering a CAGR of 6.3% during the forecast period. This growth reflects the increasing importance of infection prevention across hospitals, pharmaceutical manufacturing facilities, medical device production sites, laboratories, and food processing environments.
As healthcare systems worldwide continue to combat healthcare-associated infections (HAIs), antimicrobial resistance, and rising procedural volumes, infection control has evolved from a compliance requirement into a strategic priority for healthcare providers and life sciences organizations.
Why Infection Control Is Becoming a Strategic Priority
Healthcare facilities are under growing pressure to improve patient safety, reduce hospital readmissions, and meet stringent regulatory standards. HAIs remain one of the most significant challenges for healthcare systems, contributing to increased morbidity, mortality, and healthcare costs.
Several interconnected factors are driving sustained demand for infection control solutions:
- Rising prevalence of healthcare-associated infections (HAIs)
- Increasing number of surgical and minimally invasive procedures
- Greater adoption of advanced sterilization and reprocessing technologies
- Expanding focus on food product sterilization and disinfection
- Technological innovations in sterilization equipment
- Growing trend of outsourcing infection control services among hospitals, pharmaceutical companies, and medical device manufacturers
Together, these trends are creating a robust foundation for long-term market expansion.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1084
The Growing Burden of Healthcare-Associated Infections
HAIs continue to affect millions of patients globally each year. Infections acquired during hospital stays can lead to prolonged hospitalization, additional surgical interventions, intensive care admissions, and higher treatment costs.
To address this challenge, healthcare providers are investing heavily in:
- Sterilization and decontamination equipment
- Surface disinfection systems
- Hand hygiene solutions
- Automated endoscope reprocessors
- Sterile processing consumables
- Environmental monitoring technologies
Regulatory agencies and accreditation bodies are also strengthening infection prevention requirements, further accelerating adoption of advanced infection control products and services.
Surgical Volume Growth Is Expanding Sterilization Demand
The steady rise in elective surgeries, orthopedic procedures, cardiovascular interventions, and outpatient surgical services is significantly increasing the demand for reliable sterilization solutions.
Modern surgical environments require rapid instrument turnaround while maintaining the highest standards of sterility. This has increased the adoption of:
- Steam sterilizers
- Low-temperature sterilization systems
- Washer-disinfectors
- Sterilization containers
- Automated instrument tracking and reprocessing systems
Hospitals are increasingly seeking integrated sterile processing workflows that improve operational efficiency while minimizing the risk of cross-contamination.
Technology Innovation Is Transforming Infection Control
One of the most important growth drivers is the rapid advancement of sterilization and disinfection technologies.
Key innovation areas include:
- Low-temperature hydrogen peroxide sterilization
- Automated endoscope reprocessing
- Smart sterilization monitoring systems
- IoT-enabled equipment diagnostics
- AI-assisted workflow optimization
- Enhanced biological and chemical indicators
- Eco-friendly disinfectant formulations
These innovations help healthcare facilities improve sterilization accuracy, reduce human error, optimize resource utilization, and comply with increasingly complex regulatory standards.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1084
Outsourcing Is Reshaping the Competitive Landscape
Hospitals, pharmaceutical companies, and medical device manufacturers are increasingly outsourcing specialized infection control functions to dedicated service providers.
Benefits of outsourcing include:
- Access to specialized expertise
- Reduced capital expenditure
- Improved regulatory compliance
- Faster scalability
- Enhanced operational efficiency
- Lower maintenance and staffing burdens
Contract sterilization services have become particularly important for pharmaceutical and medical device companies that require validated sterilization processes for global product distribution.
This trend is creating significant opportunities for companies that offer contract sterilization, decontamination, and infection prevention services.
Leading Companies Driving Market Growth
The infection control market is highly competitive and is led by several global players with strong technology portfolios, extensive distribution networks, and significant R&D capabilities.
Major companies include:
- STERIS (US)
- Reckitt Benckiser Group plc. (UK)
- Fortive (US)
- Sotera Health (US)
- Solventum (US)
These companies are pursuing both organic growth strategies (new product launches, product approvals, and innovation) and inorganic strategies (acquisitions, partnerships, and geographic expansion) to strengthen their market positions.
STERIS: Strengthening Leadership Through Strategic Expansion
STERIS is widely recognized as a global leader in infection prevention and contamination control.
Its portfolio includes:
- Steam sterilizers
- Low-temperature sterilizers
- Washer-disinfectors
- Automated endoscope reprocessors
- Cleaning and disinfecting chemicals
- Surgical support products
- Sterile processing consumables
- Contract sterilization services
A significant strategic development occurred in August 2023, when STERIS acquired the surgical instrumentation, laparoscopic instrumentation, and sterilization container assets from Becton, Dickinson and Company.
This acquisition strengthened STERIS’s healthcare division by:
- Expanding its surgical instrumentation portfolio
- Enhancing its sterilization container offerings
- Broadening its customer reach
- Improving cross-selling opportunities within hospital sterile processing departments
Through continuous innovation and targeted acquisitions, STERIS has reinforced its position as a trusted partner for hospitals, pharmaceutical manufacturers, and research institutions worldwide.
Reckitt Benckiser: Leveraging Global Hygiene Brands
Reckitt Benckiser is a major force in the hygiene and infection control segment, with globally recognized brands such as Dettol and Lysol.
Its infection control portfolio includes:
- Disinfectants and antiseptics
- Hand hygiene products
- Surface disinfectants
- Sanitizers
- Germ-protection solutions for consumer and institutional use
The company demonstrated its infection control capabilities during the COVID-19 pandemic by significantly increasing production and distribution of disinfectant products worldwide.
Reckitt’s strategy focuses on:
- Strengthening its core hygiene and health brands
- Expanding B2B and institutional channels
- Investing in germ-protection formulation innovation
- Increasing penetration in healthcare, hospitality, education, and commercial facilities
Its extensive global distribution network provides a significant competitive advantage in both developed and emerging markets.
Fortive and ASP: A Transformational Acquisition
Fortive’s acquisition of Advanced Sterilization Products (ASP) has been one of the most influential developments in the infection control industry.
ASP is a recognized leader in sterilization and high-level disinfection technologies, particularly in hospital reprocessing applications.
The acquisition enabled Fortive to:
- Expand its infection prevention portfolio
- Strengthen its presence in hospital sterilization and reprocessing
- Access ASP’s established global customer base
- Enhance its recurring revenue opportunities through consumables and service offerings
This strategic move has significantly improved Fortive’s competitive position in the rapidly growing sterilization and disinfection segment.
Solventum: A New Independent Healthcare Innovator
In April 2024, Solventum completed its spinoff from 3M and began trading independently on the New York Stock Exchange under the ticker symbol “SOLV.”
As an independent company, Solventum is focused on advancing healthcare solutions by combining material science, data science, and clinical expertise.
The spinoff provides several strategic advantages:
- Sharper focus on healthcare markets
- Greater operational agility
- Faster decision-making
- Increased flexibility for targeted investments
- Enhanced ability to pursue infection prevention innovation
By operating independently from 3M, Solventum can prioritize growth opportunities in infection prevention, wound care, medical technologies, and healthcare data solutions without broader conglomerate constraints.
This repositioning is expected to accelerate innovation and strengthen the company’s presence in the global infection control market.
Sotera Health: Expanding Through Facility Growth
Sotera Health has strengthened its market position by expanding its sterilization and laboratory services facility footprint across the United States.
The company benefits from growing demand for:
- Gamma sterilization
- Ethylene oxide sterilization
- Electron beam sterilization
- Laboratory testing and validation services
Its infrastructure expansion strategy enables it to support increasing sterilization requirements from medical device manufacturers, pharmaceutical companies, and healthcare product suppliers.
Market Ranking and Competitive Dynamics
The top five players collectively hold a significant share of the global infection control market due to their:
- Broad product portfolios
- Strong R&D capabilities
- Global service networks
- Regulatory expertise
- Established customer relationships
Competitive strengths include:
| Company | Key Strength |
|---|---|
| STERIS | Strategic partnerships and acquisitions |
| Reckitt Benckiser | Worldwide brand reach and distribution |
| Fortive | Expanded sterilization portfolio through ASP |
| Sotera Health | Growing sterilization facility footprint |
| Solventum | Independent innovation focus and operational agility |
The recent strategic moves involving ASP and Solventum have reshaped the competitive landscape and intensified competition across sterilization, disinfection, and infection prevention segments.
Emerging Opportunities Through 2030
Several high-growth opportunities are expected to shape the next phase of market expansion.
1. Automated Endoscope Reprocessing
Increasing endoscopy procedure volumes are driving demand for automated, validated reprocessing systems that reduce contamination risks and improve workflow efficiency.
2. Low-Temperature Sterilization
The growing use of heat-sensitive surgical instruments and medical devices is accelerating adoption of hydrogen peroxide and other low-temperature sterilization technologies.
3. Sustainable Infection Control Solutions
Healthcare organizations are seeking environmentally responsible disinfectants, reusable sterilization systems, and energy-efficient equipment to support sustainability goals.
4. Digital Sterile Processing
Integration of tracking software, RFID systems, and real-time monitoring platforms is creating opportunities for smart sterile processing departments with improved traceability and compliance.
5. Emerging Market Healthcare Infrastructure
Rapid hospital construction and healthcare modernization in Asia-Pacific, Latin America, and the Middle East are expected to generate substantial demand for infection control equipment and services.
Future Outlook
The infection control market is entering a period of sustained and strategically important growth. With revenues expected to increase from USD 57.31 billion in 2025 to USD 77.67 billion by 2030, the sector is benefiting from powerful structural drivers that extend well beyond temporary public health emergencies.
The convergence of rising HAI awareness, increasing surgical volumes, advanced sterilization technologies, outsourcing trends, and stricter regulatory requirements is transforming infection prevention into a critical component of healthcare quality and operational performance.
Industry leaders such as STERIS, Reckitt Benckiser, Fortive, Sotera Health, and Solventum are actively strengthening their positions through acquisitions, innovation, facility expansion, and strategic realignment. Their investments are accelerating the development of more efficient, automated, and reliable infection control solutions for healthcare and life sciences organizations worldwide.
As hospitals, pharmaceutical manufacturers, and medical device companies continue to prioritize patient safety, regulatory compliance, and operational efficiency, infection control will remain one of the most essential and resilient segments of the global healthcare industry through 2030 and beyond.
Get Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1084